InsiderSignalSign in

← Insider buys

CORT

Corcept Therapeutics Incorporated · Healthcare

Insiders bought $3.3M of Corcept Therapeutics Incorporated in the last 12 months

1 insider bought on 1 day.

$3.3MBought, 12 mo

$94.8MSold, 12 mo

$9.3BMarket cap

CORT over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

G Leonard Baker JrDirector · 1 day$3.3M

CORT after insider buys

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Every filing

185 insider filings since 2016, newest first

James N Wilson · Director

$1.1M−0.9%Oct 16

Roberto Wandenkolk Vieira · President, Oncology

$967K−67.9%Oct 5

Joseph Douglas Lyon · Insider

$1.2M−63.8%Oct 5

Sean Maduck · Insider

$2.9M−71.6%Oct 5

Roberto Wandenkolk Vieira · President, Oncology

$30K−7.0%Sep 18

Joseph Douglas Lyon · Insider

$1.1M−63.8%Sep 16

James N Wilson · Director

$1.1M−0.9%Sep 16

Sean Maduck · Insider

$2.9M−71.9%Sep 3

Roberto Wandenkolk Vieira · President, Oncology

$6.5M−93.2%Sep 3

Kimberly Park · Director

$3.3M−100.0%Aug 28

Sean Maduck · Insider

$3.9M−76.0%Aug 27

David L Mahoney · Director

$12.3M−8.4%Aug 20

Sean Maduck · Insider

$419K−27.3%Aug 18

James N Wilson · Director

$1.1M−0.9%Aug 18

Gary Charles Robb · Chief Business Officer

$1.2M−20.1%Aug 18

Sean Maduck · Insider

$118K−9.6%Aug 12

William Guyer · Chief Development Officer

$1.8M−80.4%Aug 12

William Guyer · Chief Development Officer

$419K−48.1%Aug 6

Sean Maduck · Insider

$2.3M−67.5%Aug 5

Joseph Douglas Lyon · Insider

$176K−21.9%Aug 5

Atabak Mokari · Chief Financial Officer

$9.2M−83.2%Aug 3

James N Wilson · Director

$883K−0.9%Jul 17

Atabak Mokari · Chief Financial Officer

$3.5M−71.3%Jul 17

William Guyer · Chief Development Officer

$1.9M−83.4%Jul 8

Sean Maduck · Insider

$2.2M−71.9%Jul 6

James N Wilson · Director

$832K−0.9%Jun 18

David L Mahoney · Director

$1.7M−43.3%Jun 18

Atabak Mokari · Chief Financial Officer

$3.2M−71.3%Jun 17

William Guyer · Chief Development Officer

$1.4M−83.4%Jun 4

Sean Maduck · Insider

$1.8M−73.6%Jun 3

Atabak Mokari · Chief Financial Officer

$2.8M−72.4%Jun 3

Joseph K Belanoff · Chief Executive Officer

$895K−0.5%Jun 2

Joseph Douglas Lyon · Insider

$325K−44.5%May 29

Sean Maduck · Insider

$4.9M−89.3%May 29

William Guyer · Chief Development Officer

$1.0M−90.0%May 7

Joseph K Belanoff · CEO

$2.0M−1.0%May 5

William Guyer · Chief Development Officer

$819K−90.0%Apr 8

Joseph K Belanoff · CEO

$1.3M−1.0%Mar 27

William Guyer · Chief Development Officer

$424K−84.0%Mar 24

G Leonard Baker Jr · Director

$3.3M+2.0%Mar 19

William Guyer · Chief Development Officer

$296K−79.0%Mar 6

William Guyer · Chief Development Officer

$817K−94.0%Feb 5

William Guyer · Chief Development Officer

$704K−94.0%Jan 8

Joseph K Belanoff · CEO

$3.2M−1.0%Dec 3

Sean Maduck · Insider

$1.6M−15.0%Dec 3

Joseph Douglas Lyon · Insider

$398K−32.0%Dec 3

William Guyer · Chief Development Officer

$1.6M−94.0%Dec 3

William Guyer · Chief Development Officer

$364K−85.0%Dec 3

Gary Charles Robb · Chief Business Officer

$147K−6.0%Nov 26

Joseph Douglas Lyon · Insider

$80K−14.0%Nov 26

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.